WO1999026647A1 - Utilisation de proteine de liaison a l'heparine pour la modulation ou la prophylaxie de l'apoptose des cellules de mammiferes - Google Patents
Utilisation de proteine de liaison a l'heparine pour la modulation ou la prophylaxie de l'apoptose des cellules de mammiferes Download PDFInfo
- Publication number
- WO1999026647A1 WO1999026647A1 PCT/DK1998/000510 DK9800510W WO9926647A1 WO 1999026647 A1 WO1999026647 A1 WO 1999026647A1 DK 9800510 W DK9800510 W DK 9800510W WO 9926647 A1 WO9926647 A1 WO 9926647A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- hbp
- heparin
- binding protein
- mammalian
- Prior art date
Links
- 102100030009 Azurocidin Human genes 0.000 title claims abstract description 244
- 101710154607 Azurocidin Proteins 0.000 title claims abstract description 231
- 230000006907 apoptotic process Effects 0.000 title claims abstract description 41
- 210000004962 mammalian cell Anatomy 0.000 title claims abstract description 23
- 238000011321 prophylaxis Methods 0.000 title description 2
- 241000124008 Mammalia Species 0.000 claims abstract description 20
- 239000012634 fragment Substances 0.000 claims abstract description 18
- 230000003247 decreasing effect Effects 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 189
- 238000000034 method Methods 0.000 claims description 53
- 108090000623 proteins and genes Proteins 0.000 claims description 49
- 102000004169 proteins and genes Human genes 0.000 claims description 39
- 210000002889 endothelial cell Anatomy 0.000 claims description 34
- 150000007523 nucleic acids Chemical group 0.000 claims description 32
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 22
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims description 18
- 241000282414 Homo sapiens Species 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 14
- 230000007423 decrease Effects 0.000 claims description 11
- 210000001616 monocyte Anatomy 0.000 claims description 11
- 230000002438 mitochondrial effect Effects 0.000 claims description 10
- 210000004153 islets of langerhan Anatomy 0.000 claims description 9
- 239000011159 matrix material Substances 0.000 claims description 9
- 230000008685 targeting Effects 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 8
- 210000002569 neuron Anatomy 0.000 claims description 8
- 102000004877 Insulin Human genes 0.000 claims description 7
- 108090001061 Insulin Proteins 0.000 claims description 7
- 239000002975 chemoattractant Substances 0.000 claims description 7
- 210000000224 granular leucocyte Anatomy 0.000 claims description 7
- 229940125396 insulin Drugs 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 5
- 230000009471 action Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 2
- 208000018360 neuromuscular disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 53
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 36
- 235000018102 proteins Nutrition 0.000 description 36
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 35
- 102000016611 Proteoglycans Human genes 0.000 description 29
- 235000002639 sodium chloride Nutrition 0.000 description 29
- 108010067787 Proteoglycans Proteins 0.000 description 28
- 230000000694 effects Effects 0.000 description 26
- 239000011780 sodium chloride Substances 0.000 description 26
- 239000002609 medium Substances 0.000 description 25
- 101000793686 Homo sapiens Azurocidin Proteins 0.000 description 24
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 20
- 239000000872 buffer Substances 0.000 description 20
- 229920002971 Heparan sulfate Polymers 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 16
- 206010012601 diabetes mellitus Diseases 0.000 description 16
- 238000011534 incubation Methods 0.000 description 16
- 239000002953 phosphate buffered saline Substances 0.000 description 16
- 241000283973 Oryctolagus cuniculus Species 0.000 description 15
- 102100024065 Inhibitor of growth protein 1 Human genes 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 239000012894 fetal calf serum Substances 0.000 description 12
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 9
- 230000010076 replication Effects 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 241000233866 Fungi Species 0.000 description 8
- 108090000054 Syndecan-2 Proteins 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 230000002538 fungal effect Effects 0.000 description 8
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 8
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 7
- 239000013504 Triton X-100 Substances 0.000 description 7
- 229920004890 Triton X-100 Polymers 0.000 description 7
- 230000008045 co-localization Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 108010083213 heparitinsulfate lyase Proteins 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 229920000936 Agarose Polymers 0.000 description 6
- 240000006439 Aspergillus oryzae Species 0.000 description 6
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 6
- 108090000819 Chondroitin-sulfate-ABC endolyases Proteins 0.000 description 6
- 102000037716 Chondroitin-sulfate-ABC endolyases Human genes 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 108010008211 N-Formylmethionine Leucyl-Phenylalanine Proteins 0.000 description 6
- -1 ar- ginine Chemical class 0.000 description 6
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 6
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 229920000669 heparin Polymers 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- 210000003470 mitochondria Anatomy 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 239000004382 Amylase Substances 0.000 description 5
- 108010065511 Amylases Proteins 0.000 description 5
- 102000013142 Amylases Human genes 0.000 description 5
- 241000228212 Aspergillus Species 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 102000003992 Peroxidases Human genes 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 235000019418 amylase Nutrition 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 239000006167 equilibration buffer Substances 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108040007629 peroxidase activity proteins Proteins 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 5
- 229960001052 streptozocin Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 241000351920 Aspergillus nidulans Species 0.000 description 4
- 244000063299 Bacillus subtilis Species 0.000 description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 description 4
- 229920002271 DEAE-Sepharose Polymers 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 102000003711 Syndecan-2 Human genes 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 108010048241 acetamidase Proteins 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- SDZRWUKZFQQKKV-JHADDHBZSA-N cytochalasin D Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@H]\3[C@]2([C@@H](/C=C/[C@@](C)(O)C(=O)[C@@H](C)C/C=C/3)OC(C)=O)C(=O)N1)=C)C)C1=CC=CC=C1 SDZRWUKZFQQKKV-JHADDHBZSA-N 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000011533 pre-incubation Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 3
- 108010037870 Anthranilate Synthase Proteins 0.000 description 3
- 241000228245 Aspergillus niger Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108091016585 CD44 antigen Proteins 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 229920001287 Chondroitin sulfate Polymers 0.000 description 3
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical class OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 3
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 235000010724 Wisteria floribunda Nutrition 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229940059329 chondroitin sulfate Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 3
- 108010052968 leupeptin Proteins 0.000 description 3
- 210000003622 mature neutrocyte Anatomy 0.000 description 3
- 230000003228 microsomal effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 108010091212 pepstatin Proteins 0.000 description 3
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000235349 Ascomycota Species 0.000 description 2
- 101000690713 Aspergillus niger Alpha-glucosidase Proteins 0.000 description 2
- 101000757144 Aspergillus niger Glucoamylase Proteins 0.000 description 2
- 108091007065 BIRCs Proteins 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000193422 Bacillus lentus Species 0.000 description 2
- 241000194108 Bacillus licheniformis Species 0.000 description 2
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 2
- 241000221198 Basidiomycota Species 0.000 description 2
- 241000233652 Chytridiomycota Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 229920000045 Dermatan sulfate Polymers 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 241000223221 Fusarium oxysporum Species 0.000 description 2
- 101150108358 GLAA gene Proteins 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000010956 Glypican Human genes 0.000 description 2
- 108050001154 Glypican Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 102100027612 Kallikrein-11 Human genes 0.000 description 2
- 208000007976 Ketosis Diseases 0.000 description 2
- 241000235649 Kluyveromyces Species 0.000 description 2
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 2
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 2
- 241000233654 Oomycetes Species 0.000 description 2
- 241000228143 Penicillium Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 241000235346 Schizosaccharomyces Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 108090000058 Syndecan-1 Proteins 0.000 description 2
- 102000003705 Syndecan-1 Human genes 0.000 description 2
- 108090000068 Syndecan-3 Proteins 0.000 description 2
- 102000003698 Syndecan-3 Human genes 0.000 description 2
- 108010055215 Syndecan-4 Proteins 0.000 description 2
- 102100037220 Syndecan-4 Human genes 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 2
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 2
- 101710152431 Trypsin-like protease Proteins 0.000 description 2
- 241000758405 Zoopagomycotina Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 108090000637 alpha-Amylases Proteins 0.000 description 2
- 102000004139 alpha-Amylases Human genes 0.000 description 2
- 229940024171 alpha-amylase Drugs 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 2
- 229940051593 dermatan sulfate Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108010049224 perlecan Proteins 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 101150054232 pyrG gene Proteins 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- KUHSEZKIEJYEHN-UHFFFAOYSA-N 2-amino-3-hydroxypropanoic acid;2-aminopropanoic acid Chemical compound CC(N)C(O)=O.OCC(N)C(O)=O KUHSEZKIEJYEHN-UHFFFAOYSA-N 0.000 description 1
- IAJOBQBIJHVGMQ-UHFFFAOYSA-N 2-amino-4-[hydroxy(methyl)phosphoryl]butanoic acid Chemical compound CP(O)(=O)CCC(N)C(O)=O IAJOBQBIJHVGMQ-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241001578974 Achlya <moth> Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 description 1
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
- BUQICHWNXBIBOG-LMVFSUKVSA-N Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)N BUQICHWNXBIBOG-LMVFSUKVSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 102100034044 All-trans-retinol dehydrogenase [NAD(+)] ADH1B Human genes 0.000 description 1
- 101710193111 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 description 1
- 241001136561 Allomyces Species 0.000 description 1
- 241000223600 Alternaria Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000534414 Anotopterus nikparini Species 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
- 101000961203 Aspergillus awamori Glucoamylase Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 1
- 101000775727 Bacillus amyloliquefaciens Alpha-amylase Proteins 0.000 description 1
- 241000193752 Bacillus circulans Species 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 101000695691 Bacillus licheniformis Beta-lactamase Proteins 0.000 description 1
- 108010029675 Bacillus licheniformis alpha-amylase Proteins 0.000 description 1
- 241000194107 Bacillus megaterium Species 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 102100030981 Beta-alanine-activating enzyme Human genes 0.000 description 1
- 241000235432 Blastocladiella Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 241000193764 Brevibacillus brevis Species 0.000 description 1
- 241000235172 Bullera Species 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 101100479039 Caenorhabditis elegans aars-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102100037633 Centrin-3 Human genes 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241001279801 Coelomomyces Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000490729 Cryptococcaceae Species 0.000 description 1
- 241000221199 Cryptococcus <basidiomycete yeast> Species 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 101100342470 Dictyostelium discoideum pkbA gene Proteins 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 101100385973 Escherichia coli (strain K12) cycA gene Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 241000221207 Filobasidium Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 101100001650 Geobacillus stearothermophilus amyM gene Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 239000005561 Glufosinate Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101150009006 HIS3 gene Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 101100295959 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) arcB gene Proteins 0.000 description 1
- 101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 1
- 108010022901 Heparin Lyase Proteins 0.000 description 1
- 101000773364 Homo sapiens Beta-alanine-activating enzyme Proteins 0.000 description 1
- 101000880522 Homo sapiens Centrin-3 Proteins 0.000 description 1
- 101000907931 Homo sapiens Centromere protein K Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003781 Inhibitor of growth protein 1 Human genes 0.000 description 1
- 108090000191 Inhibitor of growth protein 1 Proteins 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- 108010077861 Kininogens Proteins 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- 241000235087 Lachancea kluyveri Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000321520 Leptomitales Species 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101150068888 MET3 gene Proteins 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 101100022915 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-11 gene Proteins 0.000 description 1
- 102100033174 Neutrophil elastase Human genes 0.000 description 1
- 108090000913 Nitrate Reductases Proteins 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 description 1
- 101710113020 Ornithine transcarbamylase, mitochondrial Proteins 0.000 description 1
- 102100037214 Orotidine 5'-phosphate decarboxylase Human genes 0.000 description 1
- 108010055012 Orotidine-5'-phosphate decarboxylase Proteins 0.000 description 1
- 241000194109 Paenibacillus lautus Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 241000221535 Pucciniales Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 241000235403 Rhizomucor miehei Species 0.000 description 1
- 101000968489 Rhizomucor miehei Lipase Proteins 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
- 241000223252 Rhodotorula Species 0.000 description 1
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 description 1
- 101900354623 Saccharomyces cerevisiae Galactokinase Proteins 0.000 description 1
- 235000001006 Saccharomyces cerevisiae var diastaticus Nutrition 0.000 description 1
- 244000206963 Saccharomyces cerevisiae var. diastaticus Species 0.000 description 1
- 241000204893 Saccharomyces douglasii Species 0.000 description 1
- 241001407717 Saccharomyces norbensis Species 0.000 description 1
- 241001123227 Saccharomyces pastorianus Species 0.000 description 1
- 241000235344 Saccharomycetaceae Species 0.000 description 1
- 241000235343 Saccharomycetales Species 0.000 description 1
- 241001326564 Saccharomycotina Species 0.000 description 1
- 101100022918 Schizosaccharomyces pombe (strain 972 / ATCC 24843) sua1 gene Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 241000228389 Sporidiobolus Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101100309436 Streptococcus mutans serotype c (strain ATCC 700610 / UA159) ftf gene Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000187432 Streptomyces coelicolor Species 0.000 description 1
- 101100370749 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) trpC1 gene Proteins 0.000 description 1
- 241000187391 Streptomyces hygroscopicus Species 0.000 description 1
- 241000187398 Streptomyces lividans Species 0.000 description 1
- 241001468239 Streptomyces murinus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101100157012 Thermoanaerobacterium saccharolyticum (strain DSM 8691 / JW/SL-YS485) xynB gene Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 101150050575 URA3 gene Proteins 0.000 description 1
- 241000221561 Ustilaginales Species 0.000 description 1
- 108091034131 VA RNA Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 241000235015 Yarrowia lipolytica Species 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- QWXOJIDBSHLIFI-UHFFFAOYSA-N [3-(1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC2CC(Cl)(C4)C3)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 QWXOJIDBSHLIFI-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 108010045649 agarase Proteins 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- JLYXXMFPNIAWKQ-SHFUYGGZSA-N alpha-hexachlorocyclohexane Chemical compound Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H](Cl)[C@H]1Cl JLYXXMFPNIAWKQ-SHFUYGGZSA-N 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 101150008194 argB gene Proteins 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 108010079785 calpain inhibitors Proteins 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 208000025434 cerebellar degeneration Diseases 0.000 description 1
- 238000004182 chemical digestion Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000002852 cysteine proteinase inhibitor Substances 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 101150005799 dagA gene Proteins 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004720 dielectrophoresis Methods 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 108010061330 glucan 1,4-alpha-maltohydrolase Proteins 0.000 description 1
- 230000035780 glucosuria Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000053110 human p33 Human genes 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 108010002685 hygromycin-B kinase Proteins 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 230000004140 ketosis Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 101150039489 lysZ gene Proteins 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000001466 metabolic labeling Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 101150095344 niaD gene Proteins 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 108090000021 oryzin Proteins 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 101150019841 penP gene Proteins 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 108010082527 phosphinothricin N-acetyltransferase Proteins 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940045627 porcine heparin Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 108091009335 proteoglycan binding proteins Proteins 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 101150025220 sacB gene Proteins 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 108010051423 streptavidin-agarose Proteins 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 101150016309 trpC gene Proteins 0.000 description 1
- 239000000717 tumor promoter Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 101150110790 xylB gene Proteins 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 238000011684 zucker rat (obese) Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Definitions
- cytochrome c may play a role in the activation of apoptogenic proteases (Reed, 1997, Cell 91 :559-562).
- Apoptosis can serve as a prominent force in sculpting the developing organism, as a major mechanism for the precise regulation of cell numbers and as a defense mechanism to remove unwanted and potentially dangerous cells.
- the inappropriate activation of apoptosis may cause or contribute to a variety of disorders (reviewed in Thompson, 1995, Science 267:1456-1461). These include virus-induced lymphocyte depletion (AIDS); cell death in neurodegenerative disorders char- acterized by the gradual loss of specific sets of neurons (e.g..
- growth factors anemia associated with chronic disease, aplastic anemia, chronic neutropenia and myelodysplastic syndromes
- disorders arising out of an acute loss of blood flow e.g. myocardial infarctions and stroke.
- treatments that can increase the apoptotic thresholds of specific cells may be beneficial in treatment of cell loss associated disorders (reviewed in Thompson, 1995, Science 267:1456-1461).
- treatments may be physiological inhibitors of apoptosis such as growth factors, extracellular matrix, CD40 ligand. neutral amino acids, zinc, estrogen, androgens.
- physiological inhibitors of apoptosis such as growth factors, extracellular matrix, CD40 ligand. neutral amino acids, zinc, estrogen, androgens.
- pharmacological agents such as calpain inhibitors, cysteine protease inhibitors, tumor promoters such as PMA, phenobarbital. alpha-hexachlorocyclohexane have been thought to act as inhibitors of apoptosis.
- Diabetes mellitus is a systemic disease characterized by disorders in the actions of insulin and other regulator)' hormones in the metabolism of carbohydrates, fats and proteins and in the structure and function of blood vessels.
- the primary symptom of diabetes is hyperglycemia, often accompanied by glucosuria the presence in urine of large amounts of glucose and polyuria. the excretion of large volumes of urine. Additional symptoms arise in chronic or long standing diabetes. These symptoms include degeneration of the walls of blood vessels. Although many different organs are affected by these vascular changes, the nerves eyes and kidneys appear to be the most susceptible. As such, long-standing diabetes mellitus, even when treated with insulin, is a leading cause of blindness.
- Type I diabetes is of juvenile onset, ketosis- prone, develops early in life with much more severe symptoms and has a near-certain prospect of later vascular involvement. Control of this type of diabetes is difficult and requires exogenous insulin administration.
- Type II diabetes is of adult onset, ketosis-resistant, develops later in life is milder and has a more gradual onset.
- the proteins lack protease activity.
- the proteins have been named human heparin-binding protein (hHBP) and porcine heparin-binding protein (pHBP). respectively, owing to their high affinity for heparin;
- hHBP human heparin-binding protein
- pHBP porcine heparin-binding protein
- CAP37 protein cationic antimicrobial protein due to its antimicrobial activity.
- HBP was originally studied because of its antibiotic and LPS binding properties (Gabay et al., 1989, Proc. Natl. Acad. Sci. U.S.A.
- a protein with the first 20 N-terminal amino acid residues identical to those of hHBP and CAP37 called azurocidin has also been isolated (J.E. Gabay et al., Proc. Natl. Acad. Sci. USA 86, 1989, p. 5610 ff; CG. Wilde et al., J. Biol. Chem. 265, 1990, p. 2038 ff.) and its antimicrobial properties have been reported (D. Campanelli et al., J. Clin. Invest. 85, 1990, p. 904 ff).
- HBP HBP has otherwise been termed CAP37 (cf. WO 91/00907, U.S. Patent Nos. 5.458,874 and 5,484.885) and azurocidin (cf. CG. Wilde et al., J. Biol. Chem. 265, 1990, p. 2038).
- HBP heparin-binding protein
- the invention is directed to a method of modulating or decreasing apoptosis in mammalian cells of a mammal, particularly beta cells of the Islets of Langerhans, nerve cells and endothe- lial cells, comprising administering to said mammal in need thereof a mammalian heparin- binding protein which in glycosylated form has (i) a molecular weight of about 28 kD as determined by SDS PAGE under reducing conditions; (ii) is stored in the azurophil granules of polymorphonuclear leukocytes and (iii) is a chemoattractant for monocytes or pharmaceutically active fragment thereof or a composition comprising said heparin-binding protein and a pharmaceutically effective carrier in an amount effective to modulate or decrease apoptosis in said cells.
- the invention is directed to the use of said heparin-binding protein (HBP) or fragment thereof for the manufacture of a medicament for the treatment or prophylaxis of a condition resulting from apoptosis as well as its use in treating or preventing said condition.
- HBP heparin-binding protein
- the invention is further directed to a composition comprising said heparin-binding protein and a mitochondrial matrix targeting protein.
- a mitochondrial matrix targeting protein' is a protein that has an N-terminal extension that functions as a targeting signal to the mitochondria.
- the targeting signal is a highly degenerate sequence having 20-30 residues capable of folding into a positively charged amphiphilic helix.
- the invention is fur- ther directed to uses of these compositions for the manufacture of a medicament for treating or preventing a disorder resulting from cell apoptosis.
- the invention is directed to a method for modulating and preventing mammalian cell apoptosis and accordingly a disorder resulting from cell apoptosis comprising administering to a mammal an effective amount of said composition.
- Figure 1 shows the effect of human HBP on MTT values in control and cytokine exposed RIN cells.
- Figure 2 shows the effect of human HBP on accumulated NO (nitrite) in control and cytokine exposed RIN cells.
- Figure 3 shows the release of HBP in the presence of PMA (Figure 3 A) or fMLP (Figure 3B) from PMNs in the presence or absence of HUVECs.
- Figure 4 shows the characterization of the binding of HBP to proteoglycans.
- Figure 4A shows HBP binding proteoglycans from 35 S-labeled endothelial cells are enriched by ion exchange chromatography and affinity purified on HBP-agarose. Fractions, eluted with a stepwise ionic strength gradient (250 - 1000 mM NaCl). are separated on SDS-PAGE and visualized by Phospho-Imaging. Uncoupled agarose is used as a control column. Molecular markers are given on the left.
- Figure 4B shows 35 S-labeled HBP-affinity purified proteoglycans. eluted with 300. 400 and 500 mM NaCl, were treated (+) with CABC or HNO2.
- FIG. 4C shows unlabelled endothelial cell proteoglycans eluted from the HBP-column with 300 mM NaCl or endothelial cell lysates. were digested with CABC and heparitinase (+) or left undigested (-). The cleavage products were separated by SDS-PAGE and transferred to Zeta-Probe membranes.
- Membranes were incubated with mAb 3G10 directed against desaturated glucuronate of heparitinase digested heparan sulfate proteoglycan core proteins. The positions of the different proteoglycans are indicated (*). Molecular markers are given on the left.
- Figure 5 shows a characterization of the internalization process.
- Endothelial cells are pretreated with diverse substances able to inhibit receptor-ligand interactions, protein synthesis or actin polymerization before addition of HBP.
- Cells are preincu- bated with heparin (TOO mg/ml) for 30 min.
- heparin TOO mg/ml
- cells are pretreated with NH 4 C1 (50 mM), cycloheximide (1 nM) or cytocholasin D (1 mM) for 60 min prior to addition of HBP (50 mg ml).
- Bound and/or internalized HBP is quantified in intact or permeabilized cells by FACS analysis.
- endothelial cells are incu- bated with HBP or buffer (control) alone followed by incubation with primary and secondary antibodies as described.
- FIG. 5B shows CHO wildtype (CHO-K1) and heparan sulfate proteoglycan deficient pgsD 677 cells are treated with HBP for indicated time periods. Cells are permeabilized and analyzed as described above.
- Figure 6 shows the subcellular fractionation of HBP-treated HUVECs. Equal amounts of protein from the various cell fractions are subjected to Western blotting using anti-HBP (upper panel) and ani-p33 (lower panel).
- Figure 7 shows binding of HBP to rp33.
- microtiter plates are coated with H kininogen, HBP or the control protein KLH (1 mg/ml) followed by the incubation of serial dilutions (starting concentration 2 mg/ml, two fold dilution) of rp33 (fusion protein) or the fusion partner MBP.
- Bound protein is detected by a rabbit antiserum raised against the fusion partner MBP (1 :2500 v/v) and a peroxidase-conjugated secondary antibody against rabbit IgG (1:3000 v/v). The absorption at 405 nm is presented in arbitrary units.
- Figure 8 shows colocalization of HBP with p33 and HBP with mitochondria.
- endothelial cells are incubated with FITC-labeled HBP (green) for 6 hours, fixed in 4% formaldehyde and incubated with an antibody against rp33 followed by a Texas Red conjugated secondary antibody against rabbit IgG (red).
- Figure 10 shows the effect of HBP on hydrogen peroxide treated cells.
- the HBP may suitably be of mammalian, in particular human or porcine, origin.
- the HBP is a mature human HBP which has at least about an 80% identity with the amino acid sequence set forth in SEQ ID NO: 1 , more preferably at least about 90%, even more preferably at least about 95%, and most preferably at least about 97% (hereinafter "homologous polypeptides"), which qualitative retain the activity of said heparin-binding protein, or a fragment thereof which inhibits the entry of a pathogen into a mononuclear (e.g., monocyte or macrophage) cells of a patient.
- a mononuclear e.g., monocyte or macrophage
- the HBP is a mature porcine HBP which has at least about an 80% identity with the amino acid sequence set forth in SEQ ID NO:2, more preferably at least about 90%, even more preferably at least about 95%, and most preferably at least about 97%, which qualitative retain the activity of said heparin-binding protein, or a fragment thereof which inhibits decreases or modulates apoptosis of mammalian cells in a mammal.
- the mammal is a human patient.
- the homologous polypeptides have an amino acid sequence which differs by five amino acids, preferably by four amino acids, more preferably by three amino acids, even more preferably by two amino acids, and most preferably by one amino acid from the amino acid sequence set forth in SEQ ID NOS: 1 or 2.
- the degree of identity between two or more amino acid sequences may be determined by means of computer programs known in the art such as GAP provided in the GCG program package (Needleman and Wunsch, 1970, Journal of Molecular Biology 48:443-453). For purposes of determining the degree of identity between two amino acid sequences for the present invention, GAP is used with the following settings: GAP creation penalty of 3.0 and GAP extension penalty of 0.1.
- amino acid sequences of the homologous polypeptides differ from the amino acid sequence set forth in SEQ ID NOS: 1 or 2 by an insertion or deletion of one or more amino acid residues and/or the substitution of one or more amino acid residues by different amino acid residues.
- amino acid changes are of a minor nature, that is, conservative amino acid substitutions that do not significantly affect the folding and/or activity of the protein; small deletions, typically of one to about 30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue; a small linker peptide of up to about 20-25 residues; or a small extension that facilitates purification by changing net charge or another function, such as a poly-histidine tract, an antigenic epitope or a binding domain.
- conservative substitutions are within the group of basic amino acids (such as ar- ginine, lysine and histidine), acidic amino acids (such as glutamic acid and aspartic acid), polar amino acids (such as glutamine and asparagine), hydrophobic amino acids (such as leucine. isoleucine and valine). aromatic amino acids (such as phenylalanine, tryptophan and tyrosine) and small amino acids (such as glycine, alanine. serine, threonine and methionine). Amino acid substitutions which do not generally alter the specific activity are known in the art and are described, e.g., by H. Neurath and R.L.
- the heparin binding protein may be encoded by a nucleic acid sequence having at least about an 80% identity with the nucleic acid sequence set forth in SEQ ID NO:3 (which encodes mature human HBP depicted in SEQ ID NO:l), SEQ ID NO:5 (which encodes a human HBP which includes the pro sequence and sequence of the mature protein, depicted in SEQ ID NO:6).
- SEQ ID NO:7 (which encodes human HBP which includes the signal sequence, the pro sequence and sequence of the mature protein, depicted in SEQ ID NO:8) or SEQ ID NO:4 (which encodes porcine HBP depicted in SEQ ID NO:2), SEQ ID NO:9 (which encodes a porcine HBP which includes the pro sequence and sequence of the mature protein depicted in SEQ ID NO: 10).
- SEQ ID NO: 1 1 (which encodes porcine HBP which includes the signal sequence, the pro sequence and sequence of the mature protein depicted in SEQ ID NO: 12). More preferably at least about 90%, even more preferably at least about 95%, and most preferably at least about 97%, as determined by agarose gel electrophoresis.
- the nucleic acid se- quence may be of genomic, cDNA, RNA. semisynthetic, synthetic origin, or any combinations thereof.
- GGCTCCAGCCCCC TTTTGGAC ATCGTTGGCGGC CGGAAGGCGA GGCCCCGCCA GTTCCCGTTC CTGGCCTCCA TTCAGAATCA AGGCAGGCAC TTCTGCGGGG GTGCCCTGAT CCATGCCCGCTTCGTGATGA CCGCGGCCAG CTGCTTCCAA AGCCAGAACC CCGGGGTTAG CACCGTGGTG CTGGGTGCCT ATGACCTGAG GCGGCGGGAG AGGCAGTCCC GCCAGACGTT TTCCATCAGCAGCATGAGCG AGAATGGCTA CGACCCCCAG CAGAACCTGA ACGACCTGAT GCTGCTTCAG CTGGACCGTG AGGCCAACCT CACCAGCAGC GTGACGATAC TGCCACTGCC TCTGCAGAACGCCACGGTGG AAGCCGGCAC CAGATGCCAG GTGGCCGGCT GGGGGGGAGCCA GCGCAGTGGGGGGCGTCTCT CCCGTTTTCC CAGGTTCGTC AACGTGACTG TGACT
- the degree of identity between two nucleic acid sequences may be determined by means of computer programs known in the art such as GAP provided in the GCG program package (Needleman and Wunsch, 1970, Journal of Molecular Biology 48:443-453). For purposes of determining the degree of identity between two nucleic acid sequences for the present inven- tion, GAP is used with the following settings: GAP creation penalty of 5.0 and GAP extension penalty of 0.3.
- Modification of the nucleic acid sequence encoding the HBP may be necessary for the synthesis of polypeptide sequences substantially similar to the HBP.
- the term "substantially simi- lar" to the HBP refers to non-naturally occurring forms of the HBP.
- These polypeptide sequences may differ in some engineered way from the HBP isolated from its native source. For example, it may be of interest to synthesize variants of the HBP where the variants differ in specific activity, thermostability, pH optimum, or the like using, e.g., site-directed mutagenesis.
- the analogous sequence may be constructed on the basis of the nucleic acid se- quence presented as the HBP encoding part of SEQ ID NOS:l, 2, 6, 8, 10, or 12, e.g., a subsequence thereof, and/or by introduction of nucleotide substitutions which do not give rise to another amino acid sequence of the HBP encoded by the nucleic acid sequence, but which corresponds to the codon usage of the host organism intended for production of the enzyme, or by introduction of nucleotide substitutions which may give rise to a different amino acid sequence.
- nucleotide substitution see, e.g., Ford ET al., 1991. in Protein Expression and Purification 2:95-107.
- amino acid residues essential to the activity of the polypeptide encoded by the isolated nucleic acid sequence of the invention may be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (see, e.g., Cunningham and Wells, 1989, Science 244:1081 1085). In the latter technique mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for HBP activity to identify amino acid residues that are critical to the activity of the molecule.
- the heparin-binding protein may also be encoded by a nucleic acid sequence that hybridizes to a nucleic acid sequence set forth in SEQ ID NOS: 3. 4, 6. 8, 10. and 12 at low to high stringency conditions.
- Low to high stringency conditions are defined as prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 ug/ml sheared and denatured salmon sperm DNA and either 25, 35 or 50% formamide for low, medium and high stringencies, respectively.
- the carrier material is washed three times each for 30 minutes using 2X SSC, 0.2% SDS preferably at least at 50°C (very low stringency), more preferably at least at 55°C (low stringency), more preferably at least at 60°C (medium stringency), more preferably at least at 65 °C (medium-high stringency), even more preferably at least at 70°C (high stringency) and most preferably at least at 75 °C (very high stringency).
- 2X SSC 0.2% SDS preferably at least at 50°C (very low stringency), more preferably at least at 55°C (low stringency), more preferably at least at 60°C (medium stringency), more preferably at least at 65 °C (medium-high stringency), even more preferably at least at 70°C (high stringency) and most preferably at least at 75 °C (very high stringency).
- a nucleic acid sequence encoding HBP may be prepared synthetically by established standard methods, e.g.. the phosphoamidite method described by S.L. Beaucage and M.H. Caruthers. Tetrahedron Letters 22, 1981, pp. 1859-1869, or the method described by Matthes et al., EMBO Journal 3, 1984, pp. 801-805.
- oligonucleo- tides are synthesized, e.g., in an automatic DNA synthesizer, purified, annealed, ligated and cloned in suitable vectors.
- the techniques used to isolate or clone a nucleic acid sequence encoding the heparin binding protein used in the method of the present invention are known in the art and include isolation from genomic DNA, preparation from cDNA, or a combination thereof.
- the cloning of the nucleic acid sequences of the present invention from such genomic DNA can be effected, e.g., by using the well known polymerase chain reaction (PCR) or antibody screening of expression libraries to detect cloned DNA fragments with shared structural features. See, e.g., Innis et al., 1990, A Guide to Methods and Application, Academic Press, New York.
- Other nucleic acid amplification procedures such as ligase chain reaction (LCR), ligated activated transcription (LAT) and nucleic acid sequence-based amplification (NASBA) may be used.
- a recombinant expression vector which may be any vector which may conveniently be subjected to recombinant DNA procedures.
- the choice of vector will often depend on the host cell into which it is to be introduced.
- the vector may be an autonomously replicating vector, i.e., a vector which exists as an extrachromoso- mal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid.
- the vector may be one which, when introduced into a host cell, is inte- grated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.
- the nucleic acid sequence encoding HBP should be operably connected to a suitable promoter sequence.
- the promoter may be any nucleic acid sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell.
- suitable promoters for directing the transcription of the nucleic acid sequence encoding HBP in mammalian cells are the SV 40 promoter (Subramani et al., Mol. Cell Biol. 1, 1981, pp. 854-864), the MT-1 (metallothionein gene) promoter (Palmiter et al., Science 222. 1983, pp.
- ade- novirus 2 major late promoter a Rous sarcoma virus (RSV) promoter, cytomegalovirus (CMV) promoter (Boshart et al., 1981, Cell 41:521-530) and a bovine papilloma virus promoter (BPV).
- RSV Rous sarcoma virus
- CMV cytomegalovirus
- BPV bovine papilloma virus promoter
- a suitable promoter for use in insect cells is the polyhedrin promoter (Vasuvedan et al.. FEBS Lett. 311. 1992, pp. 7-11).
- Suitable promoters for directing the transcription of the nucleic acid sequence encoding HBP. especially in a bacterial host cell are the promoters obtained from the E. coli lac operon, the Streptomyces coelicolor agarase gene (dagA).
- Bacillus subtilis levansu- erase gene sacB
- Bacillus licheniformis alpha-amylase gene amyL
- Bacillus stea- rothermophilus maltogenic amylase gene amyM
- Bacillus amyloliquefaciens alpha amylase gene amyQ
- Bacillus licheniformis penicillinase gene penP
- Bacillus sub- tilis xylA and xylB genes and the prokaryotic beta-lactamase gene
- promoters for directing the transcription of the nucleic acid sequence encoding HBP in a filamentous fungal host cell are promoters obtained from the genes encoding Aspergillus oryzae TAKA amylase, Rhizomucor miehei aspartic proteinase, Aspergillus niger neutral alpha-amylase, Aspergillus niger acid stable alpha-amylase, Aspergillus ni- ger or Aspergillus awamori glucoamylase (glaA), Rhizomucor miehei lipase, Aspergillus oryzae alkaline protease, Aspergillus oryzae triose phosphate isomerase, Aspergillus nidulans acetamidase, Fusarium oxysporum trypsin-like protease (as described in U.S.
- Patent No. 4,288,627 which is incorporated herein by reference
- Particularly preferred promoters for use in filamentous fungal host cells are the TAKA amylase, NA2-tpi (a hybrid of the promoters from the genes encoding Aspergillus niger neutral a amylase andAs- pergillus oryzae triose phosphate isomerase), and glaA promoters.
- useful promoters are obtained from the Saccharomyces cerevisiae enolase (ENO-1) gene, the Saccharomyces cerevisiae galactokinase gene (GAL1), the Saccharomyces cerevisiae alcohol dehydrogenase/glyceraldehyde-3 -phosphate dehydrogenase genes (ADH2/GAP). and the Saccharomyces cerevisiae 3-phosphoglycerate kinase gene.
- ENO-1 Saccharomyces cerevisiae enolase
- GAL1 Saccharomyces cerevisiae galactokinase gene
- ADH2/GAP Saccharomyces cerevisiae alcohol dehydrogenase/glyceraldehyde-3 -phosphate dehydrogenase genes
- Saccharomyces cerevisiae 3-phosphoglycerate kinase gene Other useful promoters for yeast host cells are described by Romanos et al
- the nucleic acid sequences encoding SEQ ID NOS: 1 and 2, e.g.. SEQ ID NOS:3 and 9 may be operably linked to a nucleic acid encoding a heterologous pro sequence.
- the nucleic acid encoding SEQ ID NOS:6, 8, 10, and 12. e.g., SEQ ID NOS:5, 7. 9, and 11 and may be operably linked to a nucleic acid sequence encoding a heterologous signal sequence and/or pro sequence.
- the nucleic acid sequence encoding HBP may also be operably connected to a suitable terminator, such as the human growth hormone terminator (Palmiter et al., op.
- Preferred terminators for filamentous fungal host cells are obtained from the genes encoding Aspergillus oryzae TAKA amylase, Aspergillus niger glucoamylase, Aspergillus nidulans anthranilate synthase, Aspergillus niger alpha-glucosidase, and Fusarium oxysporum trypsin-like protease.
- Preferred terminators for yeast host cells are obtained from the genes encoding Saccharomyces cerevisiae enolase, Saccharomyces cerevisiae cytochrome C (CYC1), or Saccharomyces cerevisiae glyceraldehyde-3-phosphate dehydrogenase.
- Other useful terminators for yeast host cells are described by Romanos et al., 1992, supra.
- the vector may further comprise elements such as polyadenylation signals (e.g. from SV 40 or the adenovirus 5 Elb region), transcriptional enhancer sequences (e.g. the SV 40 enhancer) and translational enhancer sequences (e.g. the ones encoding adenovirus VA RNAs).
- polyadenylation signals e.g. from SV 40 or the adenovirus 5 Elb region
- transcriptional enhancer sequences e.g. the SV 40 enhancer
- translational enhancer sequences e.g. the ones encoding adenovirus VA RNAs.
- preferred polyadenylation sequences for filamentous fungal host cells are obtained from the genes encoding Aspergillus oryzae TAKA amylase, Aspergillus niger glucoamylase, Aspergillus nidulans anthranilate synthase, and Aspergillus niger alpha-glucosidase.
- the recombinant expression vector may further comprise a DNA sequence enabling the vector to replicate in the host cell in question.
- a sequence when the host cell is a mammalian cell
- a sequence is the SV 40 or polyoma origin of replication.
- bacterial origins of replication are the origins of replication of plasmids pBR322, pUC 19, pACYC 177, pA- C YC 184, pUB 110, pE 194, pTA 1060, and pAMB 1.
- origin of replications for use in a yeast host cell are the 2 micron origin of replication, the combination of CEN6 and ARS4. and the combination of CEN3 and ARS 1.
- the origin of replication may be one having a mutation to make its function temperature-sensitive in the host cell (see, e.g., Ehrlich. 1978, Proceedings of the National Academy of Sciences USA 75: 1433).
- the vector may also comprise a selectable marker, e.g., a gene the product of which complements a defect in the host cell, such as the gene coding for dihydrofolate reductase (DHFR) or one which confers resistance to a drug, e.g., neomycin, geneticin, ampicillin, or hygromycin.
- DHFR dihydrofolate reductase
- Suitable markers for yeast host cells are ADE2, HIS3, LEU2, LYS2, MET3, TRP1, and URA3.
- a selectable marker for use in a filamentous fungal host cell may be selected from the group including, but not limited to, amdS (acetamidase), argB (ornithine carbamoyltrans- ferase), bar (phosphinothricin acetyltransferase), hygB (hygromycin phosphotransferase), niaD (nitrate reductase), pyrG (orotidine-5' -phosphate decarboxylase), sC (sulfate adenyl- transferase), trpC (anthranilate synthase), and glufosinate resistance markers, as well as equivalents from other species.
- amdS acetamidase
- argB ornithine carbamoyltrans- ferase
- bar phosphinothricin acetyltransferase
- hygB hygromycin phosphotransferas
- amdS and pyrG markers of Aspergillus nidulans or Aspergillus oryzae and the bar marker of Streptomyces hygroscopicus.
- selection may be accomplished by co transformation, e.g.. as described in WO 91/17243, where the selectable marker is on a separate vector.
- the host cell into which the expression vector is introduced may be any cell which is capable of producing HBP and is preferably a eukaryotic cell, such as invertebrate (insect) cells or vertebrate cells, e.g., Xenopus laevis oocytes or mammalian cells, in particular insect and mammalian cells.
- a eukaryotic cell such as invertebrate (insect) cells or vertebrate cells, e.g., Xenopus laevis oocytes or mammalian cells, in particular insect and mammalian cells.
- suitable mammalian cell lines are the COS (e.g., ATCC CRL 1650), BHK (e.g., ATCC CRL 1632, ATCC CCL 10) or CHO (e.g., ATCC CCL 61) cell lines.
- the host cell may be a mammalian basophilic cell or mammalian hybrid cell.
- the mammalian basophilic cell may be human, guinea pig. rabbit or rat basophilic cells.
- the mammalian basophilic cell is a rat basophilic cell.
- the rat basophilic cell may be an RBL-1 cell having the identifying characteristics of ATCC CRL- 1378 or RBL-2H3 cell having the identifying characteristics of ATCC CRL 2256.
- the mammalian basophilic cell is transfected with DNA encoding HBP using an electroporation apparatus.
- the medium used to culture the cells may be any conventional medium suitable for growing mammalian cells, such as a serum-containing or serum-free medium containing appropriate supplements, or a suitable medium for growing mammalian cells. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g. in catalogues of the American Type Culture Collection).
- the cells are then screened for antibiotic resistance. Subsequently, the selected clones are subsequently assayed for HBP activity using assays known in the art such as a chemotaxis assay and assaying for cytokine release from monocytes (see, for example, Rasmussen et al., 1996, FEBS Lett. 390:109-112).
- the host cell may be a hybrid mammalian cell.
- a myeloma line e.g., mouse, rat, human
- a myeloma line is transfected with DNA encoding HBP using the procedures described above. It may be subsequently be fused with a mammalian cell expressing an acidic proteoglycan such as a mammalian basophilic cell or mast cell using the following procedures.
- the parental cells are mixed in culture media such as RPMI-1640 and exposed to a chemical fusion agent such a polyethylene glycol (see, for example, Gefter et al., 1997, Somat. Cell
- the fusion agent is subsequently diluted out and the cells are incubated in media and HAT. Selected clones are subsequently assayed for HBP activity as described above.
- two parental cells may be fused by electrofusion.
- Membrane contact between cells are achieved by a non-uniform alternating field that leads to dielectrophoresis and cell chain formation. Fusion is then triggered by the injection of a field pulse that is strong enough to induce reversible breakdown in the membrane contact zone (see, for example, Okada et al., 1984, Biomed. Res. 5:511-566).
- cell fusion may be induced by Sendai virus (see, for example, Wainberg et al., 1973, J. Cell Biol. 57:388-396).
- the host cell may be a unicellular pathogen, e.g., a prokaryote, or a non-unicellular pathogen, e.g., a eukaryote.
- Useful unicellular cells are bacterial cells such as gram positive bacteria including, but not limited to, a Bacillus cell, e.g., Bacillus alkalophilus, Bacillus amylolique- faciens, Bacillus brevis, Bacillus circulans, Bacillus coagulans, Bacillus lautus, Bacillus len- tus, Bacillus licheniformis, Bacillus megaterium, Bacillus stearothermophilus, Bacillus sub- tilis, and Bacillus thuringiensis; or a Streptomyces cell, e.g., Streptomyces lividans or Streptomyces murinus.
- the bacterial host cell is a Bacillus lentus, Bacillus licheniformis, Bacillus stearothermophilus or Bacillus subtilis cell.
- the transformation of a bacterial host cell may, for instance, be effected by protoplast transformation (see, e.g., Chang and Cohen, 1979, Mo- lecular General Genetics 168:11 1-115), by using competent cells (see, e.g., Young and Spiz- izin, 1961, Journal of Bacteriology 81 :823-829, or Dubnar and Davidoff Abelson, 1971.
- the host cell may be a fungal cell.
- "Fungi" as used herein includes the phyla Ascomycota. Basidiomycota, Chytridiomycota, and Zygomycota (as defined by Hawksworth et al., In, Ainsworth and Bisby's Dictionary of The Fungi, 8th edition, 1995, CAB International, University' Press, Cambridge, UK) as well as the Oomycota (as cited in Hawksworth et al., 1995, supra, page 171) and all mitosporic fungi (Hawksworth et al., 1995, supra).
- Basidiomycota include mushrooms, rusts, and smuts.
- Representative groups of Chytridiomycota include, e.g., Allomyces, Blastocladiella, Coelomomyces, and aquatic fungi.
- Represen- tative groups of Oomycota include, e.g., Saprolegniomycetous aquatic fungi (water molds) such as Achlya.
- mitosporic fungi examples include Aspergillus, Penicillium, Candida, and Alternaria.
- Representative groups of Zygomycota include, e.g., Rhizopus and Mucor.
- the fungal host cell is a yeast cell.
- yeast as used herein includes ascosporogenous yeast (Endomycetales), basidiosporogenous yeast, and yeast belonging to the Fungi Imperfecti (Blastomycetes). The ascosporogenous yeasts are divided into the fami- lies Spermophthoraceae and Saccharomycetaceae.
- the latter is comprised of four subfamilies, Schizosaccharomycoideae (e.g., genus Schizosaccharomyces), Nadsonioideae, Lipomy- coideae, and Saccharomycoideae (e.g., genera Pichia, Kluyveromyces and Saccharomyces).
- the basidiosporogenous yeasts include the genera Leucosporidim, Rhodosporidium, Sporidiobolus, Filobasidium, and Filobasidiella.
- yeast belonging to the Fungi Imperfecti are divided into two families, Sporobolomycetaceae (e.g., genera Sorobolomyces and Bullera) and Cryptococcaceae (e.g., genus Candida). Since the classification of yeast may change in the future, for the purposes of this invention, yeast shall be defined as described in Biology and Activities of Yeast (Skinner, F.A., Passmore, S.M., and Davenport, R.R., eds, Soc. App. Bacteriol. Symposium Series No. 9, 1980).
- yeast and manipulation of yeast genetics are well known in the art (see, e.g., Biochemistry and Genetics of Yeast, Bacil, M., Horecker, B.J., and Stopani, A.O.M., editors, 2nd edition, 1987; The Yeasts, Rose, A.H., and Harrison, J.S., editors, 2nd edition, 1987; and The Molecular Biology of the Yeast Saccharomyces, Strathern et al., editors, 1981).
- the yeast host cell is a cell of a species of Candida, Kluyveromyces, Saccharomyces, Schizosaccharomyces, Pichia, or Yarrowia.
- the yeast host cell is a Saccharomyces carlsbergensis, Saccharomyces cerevisiae, Saccharomyces diastaticus, Saccharomyces douglasii, Saccharomyces kluyveri, Saccharomyces norbensis or Saccharomyces oviformis cell.
- the yeast host cell is a Kluyveromyces lactis cell.
- the yeast host cell is a Yarrowia lipolytica cell.
- the medium used to culture the cells may be any conventional medium suitable for growing mammalian cells, such as a serum-containing or serum-free medium containing appropriate supplements, or a suitable medium for growing insect, yeast or fungal cells. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g,. in catalogues of the American Type Culture Collection).
- the HBP produced by the cells may then be recovered from the culture medium by conventional procedures including separating the host cells from the medium by centrifugation or filtration, precipitating the proteinaceous components of the supernatant or filtrate by means of a salt, e.g., ammonium sulphate, purification by a variety of chromatographic procedures, e.g., ion exchange chromatography, affinity chromatography, or the like.
- the recombinant host cells may also produce an acid proteoglycan such as heparin sulfate. To obtain active HBP, the acid proteoglycan will need to be removed.
- This may be accomplished using a series of separation methods, ie., precipitation or column chromatography, such as reverse phase HPLC, HIC, SEC, IEC and affinity based techniques.
- the separation method may be combined with other treatments like increasing salt concentration, by change in the pH and by other means that reduce interactions between the acidic proteoglycan and HBP.
- the recombinant host cells may also produce an acid proteoglycan such as heparin sulfate. To obtain active HBP, the acid proteoglycan will need to be removed.
- an acid proteoglycan such as heparin sulfate.
- the HBP may be formulated by any of the established methods of formulating pharmaceutical compositions, e.g. as described in Remington's Pharmaceutical Sciences, 1985.
- the composition may typically be in a form suited for local or systemic injection or infusion and may, as such, be formulated with sterile water or an isotonic saline or glucose solution.
- the compositions may be sterilized by conventional sterilization techniques which are well known in the art.
- the re- suiting aqueous solutions may be packaged for use or filtered under aseptic conditions and lyophilized, the lyophilized preparation being combined with the sterile aqueous solution prior to administration.
- the composition may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as buffering agents, tonicity adjusting agents and the like, for instance sodium acetate, sodium lactate, sodium chloride. potassium chloride, calcium chloride, etc.
- concentration of HBP may vary widely, i.e. from less than about 0.5%, such as from 1%, to as much as 15-20% by weight.
- a unit dosage of the composition may typically contain from about 10 mg to about 1 g of HBP.
- HBP or pharmaceutically active fragments thereof are admimstered topically or by intravenous injection. Dosages will be prescribed by the physician according to the particular condition and the particular individual to be treated. Dosages and frequency is carefully adapted and adjusted according to parameters determined by the physician in charge.
- a preferred administration route may be e.g. injections intraperitoneally.
- Intravenous intraperitoneal injections of HBP may be given per 24 hours in the range of from 0.1-100 mg, especially 0.1-20 mg, in particular 0.1-10 mg per kg body weight.
- the dose may be given 1-4 times per 24 hours or administered continuously through a catheter.
- Compositions used in the present invention may additionally comprise a mitochondrial matrix targeting protein.
- the mitochondrial matrix targeting protein has a molecular weight of about 33 kD, binds to H- but not L-kininogen.
- the mitochondrial matrix targeting protein has an N-terminal amino acid sequence depicted in SEQ ID NO: 15, the 32 N-terminal amino acid sequence of p33 (Ghebrehiwet et al., 1994, J. Exp. Med. 179: 1809):
- mitochondrial matrix targetting protein is the zinc dependent p33 protein depicted in SEQ ID NO: 16:
- compositions used in the methods of the present invention are contemplated to be of use in treating or preventing disorders caused by apoptosis. These include but are not limited to HIV, neurodegenerative or neuromuscular diseases, ischemic stroke, anoxia, ische- mia/reperfusion damage and intoxication septic shock.
- said compositions may be used to prevent the destruction of beta cells in the Islets of Langerhans in the pancreas. Damage to such beta cells leads to diabetes mellitus.
- HBP is obtained from RBL-1 cells using the procedure described in application serial no. PCT/DK98/00275. The procedure is summarized below.
- the vectors pBlueBacIII and pcDNA3 are obtained from Invitrogen. All primers and oligos are synthesized on an Applied Biosystems Model 394 DNA synthesizer. Restriction enzymes are obtained from New England Biolabs. Pfu polymerase. used in PCR reactions is obtained from Stratagene.
- RBL-1 cells (ATCC CRL-1378) and RBL-2H3 cells (ATCC CRL-2256) are obtained from American Type Culture Collection (ATCC) in Manassas, VA.
- Cells are grown as recommended by the supplier or in RPMI 1640 culture medium (Gibco, Life Technologies) supplemented with 10% heat inactivated gamma- irradiated FCS (origin: NZ, Gibco, Life Technologies) or fetal calf serum (FCS) North American origin from HyClone or BioWhit- taker. Cells are grown in 5% CO, at 37°C in an 80% humidified atmosphere. Exponentially growing cells are used in all experiments.
- RPMI 1640 culture medium Gibco, Life Technologies
- FCS fetal calf serum
- a 770 bp BamHI-Hindlll fragment is constructed using PCR technology from a human bone marrow DNA library (Clontech) based on the human HBP amino acid sequence (Flodgaard et al, 1991, Eur. J. Biochem. 197:535-547) and the CAP 37/azurocidin DNA sequence (Morgan et al., 1991, J. Immunol. 147:3210-3214 and Almeida et al., 1991, Biochem. Biophys. Res. Commun. 177:688-695).
- This fragment contains the entire coding region of HBP, including a 19-residue signal peptide, a 7 amino acid pro-peptide, a mature part of 22 amino acids, and a 3 amino acid C-terminal extension.
- the fragment is inserted into pBlue-BacIII resulting in the plasmid pSX556.
- an oligonucleotide linker of 99 bp, covering the signal peptide and the first 4 amino acids of mature HBP (from BamHI to Eagl) is substituted for the original BamHI-Eagl fragment in pSX556 giving rise to pSX559.
- pSX556 and pSX559 described above are used as templates in PCR reactions using the primers
- PBRa 246 (5'-CCGGGGATCCAACTAGGCTGGCCCCGGTCCCGG-3 * ) (SEQ ID NO: 13 )
- PBRa247 (5'-CCGGGGATCCGATGACCCGGCTGACAGTCCTGG-3') (SEQ ID NO: 14) with a Pfu polymerase according to manufacturer's instructions (Stratagene).
- the fragments are ligated in correct orientation into the mammalian expression vector pcDNA3 (Invitrogen), linearized with BamHI, resulting in two plasmids, pcDNA3-HBP and pcDNA3-HBP pro.
- Transfection is performed according to the following procedures. 25 ⁇ g of pcDNA3-HBP or pcDNA3-HBP pro is transfected into RBL-1 cells or RBL-2H3 cells (8 x 10 6 cells are transfected using a BioRad Electroporation Apparatus with electric settings 960 uF and 300V as described by Gullberg et al., 1994, J. Biol. Chem. 269:25219-25225 and Garwicz et al., 1995, J. Biol. Chem. 270:28413-28418, or are transfected using LipofecAmine (Gibco, Life Technologies) or Superfect (Qiagen) transfection reagents as recommended by the suppliers.
- LipofecAmine Gibco, Life Technologies
- Superfect Qiagen
- HBP ELISA is a sandwich immunoassay using a monoclonal antibody as catcher and a polyclonal rabbit antibody conjugated to horseradish peroxidase as detector. Antibodies are prepared according to standard procedures by immunizing mice and rabbits with HBP purified from human buffy coat cells (Flodgaard et al..
- each well is coated with 0.5 ⁇ g monoclonal anti-hHBP dissolved in 100 ⁇ l of PBS overnight.
- the coated wells are washed three times with a solution of 5% lactose, 0.5% Byco A 0.05% Tween 20 and 0.024% thiomersal. After the last washing, the plates are left to dry at room temperature upside-down on a piece of cloth.
- the coated plates are rapped with staniol and can be stored up to three months.
- Purified hHBP is used as reference preparation.
- a working dilution of 100 ng hHBP/ml is prepared in a BSA-EDTA buffer and stored in aliquots at -80°C for a maximum of two weeks.
- Serial dilution's containing 0; 0.3; 1 ; 4 and 12 ng hHBP/ml diluted in BSA-EDTA are made fresh and 100 ⁇ l are added to each well.
- hHBP samples are also diluted in BSA-EDTA buffer and all the samples are in-cubated agitated for 1 hour at room temperature.
- the wells are emptied and washed three times with phosphate buffered saline followed by the addition of 100 ⁇ l/well diluted (1 : 1000) Fab-peroxidase conjugated rabbit anti-hHBP, and incubated agitated for 1 hour at room temperature.
- Peroxidase activity is measured using 100 ⁇ l/well TMB perborate substrate solution, resulting in a color formation measurable photometrically at 450 nm.
- the reference curve is linear when the logarithm to the absorbance is plotted against the logarithm to the dose.
- Clones with the most pronounced expression are chosen for further experiments, recloned and retested for expression levels.
- the highest HBP producers are selected and grown into mass culture or adapted to serum free or protein free medium.
- the isolation of HBP from RBL-1 cells is carried out essentially as described by Rasmussen et al., 1996, FEBS Lett. 390:109-112.
- the transfected and selected RBL-1 cells are initially filtered to remove any remaining cells and cell debris.
- the culture medium is subsequently applied to a CM-Sepharose cation-exchange column (Pharmacia and Upjohn), previously equilibrated with 50 mM sodium phosphate, pH 7.3. Unbound and loosely bound materials are eluted with equilibration buffer until baseline is achieved measured by on-line UV detection at 280 nm.
- the column is then developed with a linear gradient from 0 to 1 M sodium chloride in equilibration buffer.
- HBP eluted with about 0.7 M sodium chloride and fractions are combined based on UV absorption. Pooled fractions are diluted with two volumes of distilled water and applied on a new CM-Sepharose column. Following equilibration HBP is step eluted with 1 M sodium chloride in equilibration buffer and fractions combined based on absorption at 280 nm. Highly concentrated and pure HBP is obtained by this procedure. Fi- nal purification is carried out on a Sephadex G-25 gel-filtration column (Pharmacia & Upjohn) equipped with a UV-flow cell and equilibrated and eluted with 0.02% trifluoroacetic acid. HBP is collected based on absorption at 280 nm. The gel filtration serves mainly as a buffer exchange step to produce a stable preparation of HBP that is kept at 4°C until use.
- Day 0 Rat Insulinoma cells (RIN cells) are seeded in 200 ⁇ l medium with 10,000 cells per well.
- Day 1 After 24 hours the medium is discarded and new medium containing 0, 20 or 50 ⁇ g/ml medium of HBP is added to a total volume of 100 ⁇ l.
- Day 2 The medium in the wells without HBP is discarded and fresh medium containing 0 or 1500 units IL-1 beta and 20 ⁇ g/ml medium of HBP is added in a total volume of 200 ⁇ l.
- To the wells pretreated with HBP (cells not attached) 0 or 1500 units IL-1 Beta and 20 ⁇ g/ml medium of HBP is added in a to- tal volume of 100 ⁇ l giving a total volume of 200 ⁇ l.
- Day 5 The NO content in the medium and the accumulation of insulin are measured.
- MTT assay succinate dehydrogenase activity. a measure of apoptosis
- the results are shown in Figures 1 and 2.
- the numbers 1-6 depict the following: 1 : Control (all media changed after preincub. with HBP, 200 ⁇ l new media with HBP and cytokines added; 2: as 1 but with 20 ⁇ g/ml HBP; 3: as 1 but with 50 ⁇ g/ml HBP; 4: Control (100 ml media (with HBP and 2x cytokines) added on top of 100 ⁇ l HBP preincubation; 5: as 4 but with 20 ⁇ g/ml HBP; 6: as 4 but with 50 ⁇ g/ml HBP. It is evident from the results that treatment of beta cells with HBP results in a decreased apoptosis, but no effect on NO production.
- Beta cells are pre-incubated with HBP or control vehicle for 24 hours before treatment with varying concentrations of the NO donor, Streptozotocin. After 1-2 days of incubation at standard conditions (37°C, 5% CO 2 ) cells are assayed for apoptosis. The cells pre-incubated with HBP show less or no apoptosis as compared to control incubations. Thus, HBP prevents de- struction of the beta cells.
- Beta cells are incubated with HBP and Streptozotocin or control vehicle and Streptozotocin for 24 hours.
- the cells incubated with HBP show less or no apoptosis as compared to control incubations.
- HBP prevents destruction of the beta cells.
- Wistar adult rats are pre-treated with a sustained release of HBP or control vehicle from a subcutaneouslv implanted mini osmotic pump on the back. 24 or 48 hours later, the rats are rendered diabetic by intraperitoneal injection of Streptozotocin in the tail. Blood glucose and urinary excretion of glucose and albumin are monitored for 2-3 weeks. The HBP treated rats show a significant lower frequency of diabetes symptoms than the controls. Finally, the animals are sacrificed and histological examination of the pancreas is performed. The HBP treated rats show no or little beta cell destruction.
- Spontaneously diabetic NOD nonobese diabetic mice are treated with HBP or control vehicle for 1-2 months.
- the HBP treated mice show a significant lower frequency of diabetes symptoms than the controls.
- the animals are sacrificed and histological examination of the pancreas is performed.
- the HBP treated mice show no or little beta cell destruction.
- Human umbilical vein endothelial cells are isolated by digestion with collagenase
- Wildtype CHO cells (CHO-Kl) and the heparan sulfate deficient variant (pgsD-677) (Murphy Ulrich et al., 1988, J. Biol. Chem. 272:24363-243670). are grown in F12K Nutrient mixture with Kaighn's modification (GIBCO) supplemented with fetal calf serum and antibiotics.
- GEBCO Kaighn's modification
- Recombinant human HBP is produced using a baculovirus expression system in Sf9 insect cells (BRL) and purified as described (Rasmussen et al., 1996, FEBS Lett. 390:109-112).
- the mouse monoclonal antibody (mab) 2F23C3 and rabbit antisera against recombinant HBP (anti-HBP) were affinity-purified.
- the antiserum against mitochondrial protein p33/gClqR (anti-p33) was raised in rabbits and affinity-purified (Dedio et al., 1998, J. Immunol
- mice mab 3G10 recognizing desaturated glucuronate reactive with heparitinase-digested heparan sulfate proteoglycan core proteins has been characterized previously (David et al., 1992, J. Cell Biol. 119:961-975).
- Texas red-conjugated goat anti-rabbit immunoglobulin IgG and goat anti-mouse IgG are from Jackson ImmunoResearch Laborato- ries Inc.
- Endothelial cells are cultured in the presence of 100 mCi/ml Na 2 35 SO 4 (specific activity) (Amersham International, Buckinghamshire, UK) or 50 mCi/ml 3 H leucine (Amersham) diluted in endothelial cell culture media. After 24 hours, the cells are washed 4 times with cold phosphate buffered saline (PBS, GIBCO) and lysed for 1 hour at 4°C on a shaker.
- PBS cold phosphate buffered saline
- the lysis buffer consisted of 1% Triton-X-100, 20 mM Tris-HCl, 1 mM CaCl,, 1 mM MgCl 2 , 2 mM PMSF, 5 mM 1,10-phenanthroline, 4 mg/ml leupeptin, 4 mg/ml pepstatin A and 100 mg/ml aprotonin at pH 8.0.
- the lysate is centrifuged at 10,000 g for 30 minutes at 4°C and the pellet is discarded.
- endothelial cell lysate containing 0.2 M NaCl
- DEAE Sepharose Fast Flow (Pharmacia Biotech AB, Uppsala, Sweden) pre-equilibrated with 0.2 M NaCl, 20 mM Tris-HCl, 0.1% Triton-X-100 and 1 mM PMSF at pH 8.0.
- the DEAE-Sepharose is washed with 10 gel volumes of 0.2 M NaCl, 50 mM Na-acetate, 0.1% Triton-X-100, 1 mM PMSF at pH 4.0 and then eluted with 1 M NaCl in buffer A (20 mM Tris HCl, 0.1% Triton-X-100 and 1 mM PMSF at pH 7.4).
- Biotinylated HBP (5 mg) is bound to 2.5 ml streptavidin-agarose (Sigma). Uncoupled agarose is used as a control column. Successful coupling of HBP to the column is confirmed by SDS PAGE (data not shown) .
- Equal gel volumes of the HBP- and control agarose are equilibrated at 4°C with buffer A containing 150 mM NaCl, 1 mM CaCl 2 and 1 mM MgCl 2 .
- the material eluted from the DEAE-Sepharose is dialyzed against equilibration buffer, incubated end over end with the control column for 2 h at 4°C followed by the HBP-column for 2 h at 4°C
- the HBP- and control columns are washed with 10 gel volumes of equilibration buffer and then eluted with 5 gel volumes each of a discontinuous NaCl gradient ranging from 250 to 1000 mM NaCl in buffer A.
- Samples from eluted material are separated by 4-16% SDS-PAGE under reducing or non-reducing conditions. Analysis of radioactive material is done on gels exposed to X-ray film or to Fuji Imaging plates (Biolmaging Analyzer Bas2000, Fuji Photo Film Co., LTD, Tokyo, Japan). When the samples contained 3 H-leucine-labeled material, gels are treated with 1.3 M Na-salicylate in 5 mM NaH 2 PO 4 at pH 7 (Chamberlain, 1979, Anal. Biochem. 98:132-135) prior to exposure to X-ray film.
- Radiolabeled HBP-binding material eluted from the HBP-streptavidin agarose is treated over night at room temperature with either 60 mU/ml CABC (Sigma), 4 U/ml heparinase III (Sigma), or a combination of both in 50 mM Tris-HCl, 0.1 M NaCl at pH 7.3.
- the samples are treated with HNO, at pH 1.5 for 10 min at room temperature (Shively and Conrad, 1976, Biochemistry 15:3932-3942).
- Proteoglycans can be separated based on their size in agarose gels where they run as discrete units rather than as a broad smear (Bjornsson, 1993, Anal. Chem. 210:282-291 and Bjornsson, 1993, Anal. Chem.
- the HBP-affinity purified material is concentrated on 100 ml DEAE-Trisacryl columns (BioSepra S.A., Villeneuve la Garenne Cedex, France) and eluted with buffer A containing 1 M NaCl (5 x 50 ml).
- the concentrated samples and the sample from the original endothelial cell lysate are doubly digested with 0.5 U/ml CABC (Seikagaku Kogyo, Tokyo, Japan) and 10 mU/ml heparitinase (Seikagaku) in 100 mM NaCl, 1 mM CaCl 2 , 0.1% Triton-X-100, 50 mM 6-amino-hexanoic acid, 20 mg/ml leupeptin, 2.5 mg/ml pepstatin A, 1 mM PMSF and 50 mM HEPES at pH 7.0, for 3 hours at 37°C After separation under non-reducing conditions by 20% SDS-PAGE, materials are transferred onto Zeta-Probe membranes (Bio-Rad laboratories, Hercules, CA, USA) at 70 V, 0.5 mA for 4 hours at 4°C The membranes are blocked in 0.5% casein in PBS (buffer B) containing 0.6 M NaCl over night at 4
- the membranes are washed once in buffer B containing 0.15 M NaCl and then incubated with rabbit anti-mouse IgG conjugated with alkaline phosphatase diluted 1 :5000 in buffer B containing 0.15 M NaCl. After two washes, bound antibodies are detected using the CSPD detection system (Tropix. Bedford, MA, USA) according to the manufacturer.
- Protein samples eluted from the HBP-coupled column are separated by 12.5 % SDS-PAGE and transferred onto nitrocellulose membranes for 30 min at 100 mA.
- the membranes are blocked with 50 mM KH,PO 4 , 0.2 M NaCl. containing 5% w/v dry milk powder and 0.05% w/v Tween 20 at pH 7.4 (buffer C).
- Transferred proteins are incubated with primary antibodies (anti-rp33, anti-CDR31, anti-MBP, anti-HBP) diluted to 1 mg/ml in buffer C. Bound primary antibodies are detected by a peroxidase-conjugated secondary antibody against rabbit IgG followed by the ECL (Amersham) detection method.
- Microtiter plates are coated overnight at room temperature with HBP, H-kininogen or a control peptide KLH (1 mg/ml each) in 100 mM sodium acetate and 100 mM NaCl at pH 5.5 (Herwald et al., op. Cit.).
- Binding of the recombinant fusion protein rp33 or the fusion partner MBP (starting concentration 2 mg/ml. two fold dilutions) to the immobilized proteins is detected by a-MBP (1 :2500 v/v) followed by incubation with a peroxidase-conjugated secondary antibody directed against rabbit IgG (1 :3000 v/v) (Herwald et al., op. cit).
- the incubation steps are done in a buffer containing 50 mM KH,PO 4 , 0.2 M NaCl. contaimng 2% w/v bovine serum albumin (BSA) and 0.05% w/v Tween 20 at pH 7.4.
- BSA bovine serum albumin
- a substrate solution of 0.15% w/v diammonium 2,2-azino-bis-(3-ethyl-2,3-dihydrobenzthiazoline-6- sulfonate), (ABTS), 0.012 % H 2 O 2 in 100 mM citric acid, pH 4.5 is applied for 30 min, and the change in absorbance is determined at 405 nm.
- HBP surface plasmon resonance spectroscopy
- CM5 sensor chip Specific interactions between HBP and rp33 are studied using surface plasmon resonance spectroscopy (BIAlite, Pharmacia, Freiburg, Germany).
- HBP is coupled to a CM5 sensor chip according to the manufacturer's instructions.
- MBP and rp33 are dissolved in HEPES- Tyrodes buffer in the presence or in the absence of 50 ⁇ M Zn 2" in two fold serial dilution, with a starting concentration of 100 ⁇ g/ml.
- 30 ⁇ l of each protein sample is applied using a flow rate of 10 ml/min. After 3 min, the chip is washed with PBS to follow dissociation for 3 min. The chip is regenerated by washing with 30 mM HCl.
- the BIAevaluation 2.0 program (Pharmacia. Freiburg, Germany) is used.
- Endothelial cells grown to confluency in 12-well plates are washed once in Ml 99 with Hank ' s solution (GIBCO) and then incubated with unconjugated recombinant HBP (50 ⁇ g/ml) diluted in the same media for various periods of time at 37°C
- HBP unconjugated recombinant HBP
- the cells are washed twice with 0.5% human serum albumin (Calbiochem, La Jolla, CA. USA) in PBS and once with Ca :" and Mg + free PBS.
- Cell dissociation solution 500 ⁇ l; Sigma is added, the cells are placed at 37°C for 15 min and then harvested using a cell scraper.
- the cells After fixation in 1% formaldehyde for a minimum of 1 hour at room temperature, the cells are incubated with a mouse mAb against HBP (25 ⁇ g/ml) in PBS/0.02% azide containing 1% heat-inactivated human serum or the same solution containing 1% saponin (Sigma) and 0.0125% digitonin (Sigma).
- the cells are incubated with a FITC-conjugated secondary goat-anti-mouse antibody diluted 1:100.
- the cells (5,000/experiment) are analyzed on a FACSort (Becton Dickinson, Palo Alto, CA, USA) using a FACStation with Cellquest software.
- the control cells are incubated with either primary or both primary and secondary antibodies but not with HBP.
- the mean fluorescence intensity (MFI) is calculated on channel values. Results are given as means SD.
- the endothelial cells are pretreated with NH 4 C1 (50 mM), cytochalasin D (1 ⁇ M) or cycloheximide (1 nM) before addition of HBP (50 ⁇ g/ml).
- HBP is incubated with heparin (100 ⁇ g/ml) prior to addition of the HBP-heparin mixture to the cells.
- HBP heparan sulfate proteoglycan deficient CHO cells
- Endothelial cells grown overnight on microscopic slides are incubated with 50 ⁇ g/ml FITC labeled or unconjugated HBP in Ml 99 with Hank's solution (GIBCO) for various periods of time. After a brief wash with PBS, the endothelial cells are fixed in 4% formaldehyde for 1 hour. Cells are washed with 100 mM glycine for 1 hour and permeabilized with cold methanol for 10 min. Cells are incubated with 1% BSA in PBS prior to incubation with antibodies. The staining steps are performed so as to avoid crossreactions from secondary reagents.
- the cells are incubated up to 24 hours, fixed in formaldehyde and stained for p33. After 30 min incubation with anti-rp33 (10 ⁇ g/ml), the cells are washed and fixed with a Texas Red-conjugated goat-anti-rabbit IgG. The slides are equili- brated and mounted with SlowFade Antifade (Molecular Probes. Leiden, The Netherlands) according to manufacturer's instructions. The cells are analyzed using a Zeiss LSM 310 (Laser Scan Microscope, Oberkochen, Germany). A 590 nm filter is used to prevent interference of emitted light from the green to the red signal.
- Zeiss LSM 310 Laser Scan Microscope, Oberkochen, Germany
- Confluent endothelial cells grown in five 12-well plates were washed once in Ml 99 with Hank's solution (GIBCO). Each plate was incubated with non-conjugated recombinant wildtype HBP (25 mg/ml) in 5 ml of the same buffer for 24 h at 37°C. Cells are washed once with Ca 2" and Mg 2+ free PBS, and scraped from the plates.
- GEBCO Hank's solution
- cells After centrifugation (800 x g, 10 min) cells are resuspended in 2.5 ml of 50 mM phosphate, pH 7.4, 0.28 M sucrose, 100 ⁇ g/ml phenylmethanesulfonyl fluoride, 1 ⁇ g/ml aprotinin, 0.5 ⁇ g/ml leupeptin, 1 ⁇ g/ml pepstatin A, 3.6 ⁇ g/ml trans-epoxylsuccinyl-L-leucylamido-(4-guanidino)butane. Washed cells are pressurized with N 2 for 5 min at 350 psi at 4°C and the cavitate is collected.
- the homogenate is centrifiiged at 800 x g for 10 min and the nuclear pellet PI is discarded.
- the supernatant (SI) is further analyzed as described earlier Briefly, supernatant S 1 is centrifiiged at 20,000 x g for 20 min and the resulting supernatant S2 is collected.
- the membrane pellet P2 is washed in 5 ml of 50 mM phosphate buffer containing proteinase inhibitors and centrifuged again.
- Washed pellet, P2 is resuspended in 1 ml of phosphate buffer containing 12% (w/v) sucrose and layered on top of a 33% (w/v) sucrose cushion (10 ml) followed by centrifugation carried out at 100,000 x g for 3 h.
- the pellet P3 (vesicular fraction) was resuspended in phosphate buffer.
- the membranes at the gradient interface were collected, diluted with 30 ml of phosphate buffer and centrifuged (30,000 x g, 45 min).
- Pellet P4 membrane fraction
- Centrifugation (100,000 x g, 3 h) of supernatant S2 gave pellet P3 (microsomal fraction) and supernatant S3 (cytosolic fraction). All treatments are performed at 4°C.
- HUNEC cells are retrieved and subcultured.
- Cells in passage #1 are trypsinized and seeded (10,000 cells/well in 100 ⁇ l complete growth medium) in 96-well CulturePlates, precoated with gelatine. The cells are cultured overnight to obtain confluence. As a visual control, cells are seeded in parallel in a standard 96-well tissue culture plate ( ⁇ unc).
- the medium is changed to Ml 99 + 10% FCS, hHBP is added to final concentrations 0, 10 or 50 ⁇ g/ml and the cells are incubated for 24 hours.
- apoptosis is induced by simultaneously washing away hHBP and changing the medium to either M199 + 10% FCS or M199 without additives.
- the cells are subse- quently incubated for 24 hours.
- the D ⁇ A fragmentation is measured by the TU ⁇ EL as described in the kit sold by PharMingen method with a few modifications.
- culture medium is carefully removed and the cells are fixe by adding 200 ⁇ l 10% formaldehyde buffered in PBS (20 mM phosphate, 150 mM ⁇ aCl, pH 7.4) 0 for 30 min. at room temperature.
- the cells are washed once with PBS and permeabilized for 5 min. with 100 ⁇ l of a mix of 0.1 % sodium citrate and 0.1 % Triton X-100 at room temperature, followed by a wash with PBS.
- the TU ⁇ EL reaction is initiated by adding 50 ⁇ l of TU ⁇ EL reaction mix (5 U Tdt enzyme and 0.3 ⁇ l [ 32 P]dCTP/well in 200 mM sodium cacodylate, 25 mM Tris-HCl.
- the plate is incubated at 37°C for 1 hr. to determine the background level, wells in parallel are incubated with reaction mix without Tdt enzyme. The reaction is terminated by carefully removing the TU ⁇ EL reaction mix and washing the cells twice with PBS. Subsequently, the plate is completely dried under vacuum, 200 ⁇ l of Microscint-PS scintillation fluid is added, the plate is sealed and counted in a microplate scintillation counter (Packard TopCount). The degree of labelling is determined by subtracting the background level from the values obtained in the samples containing Tdt enzyme.
- HUVEC cells are treated with medium (control) and medium containing hydrogen peroxide as indicated for 18 hours. Apoptosis is determined as described above.
- HBP is a protein that is almost exclusively synthesized and stored in polymorphonuclear (PMN) leukocytes.
- PMN leuko- cytes are stimulated from human plasma with increasing concentrations of phorbol myristate acetate (PMA) or f-Met-Leu-Phe (fMLP) in the presence or absence of human umbilical vein endothelial cells (HUVECs).
- PMA phorbol myristate acetate
- fMLP f-Met-Leu-Phe
- HBP umbilical vein endothelial cells
- Endothelial cells are metabolically labeled with Na 2 [ 35 S]SO 4 to allow incorporation into the glycosaminoglycan chains of proteoglycans.
- Cells are lysed, the total cellular lysate was applied to DEAE-Sepharose. and the eluted material was affinity-purified on HBP covalenth bound to agarose.
- the radiolabeled material was eluted from the HBP-column by a step gradient of 250 to 500 mM NaCl, and the resultant fractions were analyzed by SDS-PAGE ( Figure 4A, left panel).
- the eluted material appears as a broad smear of bands covering a molecular weight range of approximately 40 kDA to > 400 kDa as often found for proteoglycans whereas minor amounts of unspecifically bound material was eluted from the uncoupled matrix (Figure 4A, right panel).
- a heterogeneous population of [ 35 S]-labeled molecules sticks to the HBP-Sepharose which may - at least in part - represent proteoglycans; these are referred to HBP binding sites.
- Radioactively labeled material from the HBP column was treated with chondroitinase AB c (C ABC ) t0 remove side chains of chondroitin sulfate and dermatan sulfate, or with HNO, to selectively destroy heparan sulfate side chains.
- C ABC chondroitinase AB c
- HNO HNO
- endothelial cells express six major types of proteoglycans containing glycosamino- glycan of the heparan sulfate type, i.e. perlecan, glypican. and syndecan-1, -2, -3 and —4.
- Affinity-purified HBP binding sites were treated by double digestion with heparinase III and C ABC to completely remove their heparan side chains (see above).
- proteoglycans of total HUVEC lysates are run in parallel and identified by the relative molecular masses of their core proteins: syndecan-4 (35 K). syndecan-2 (48 K), glypican (64 K), syndecan-1 (90 K), syndecan-3 (125 K). and perlecan (> 200 K), Figure 4 (right panel. from bottom to top). All the heparan sulfate-containing proteoglycans present in total HUVEC lysates are also present in the HBP-binding fraction (left panel) indicating that they represent docking sites for HBP.
- HBP internalization process FACS analyses is performed on HUVECs that are preincubated with 50 ⁇ g/ml of HBP for 0.5 h followed by extensive washes to remove the free ligand (Figure 5A).
- Permeabilized HUVECs showed a significantly higher mean fluorescence index (MFI) than intact cells suggesting that a significant fraction of the exogenously applied HBP had entered the cells.
- MFI mean fluorescence index
- Incubation in the absence of HBP resulted in a MFI similar to that of intact cells indicating that the ligand had been effectively removed.
- Preincubation of the cells with 100 ⁇ g/ml of heparin effectively prevented uptake of HBP.
- HBP internalization possibly due to competition with HBP for binding sites on heparan sulfate-containing proteoglycans.
- Incubation at 4°C significantly decreased HBP internalization for permeabilized HUVECs but not for non-permeabilized cells demonstrating that HBP internalization is an energy-dependent process.
- Addition of NH4C1 which has been shown to interfere with ligand release from internalized receptors thus leading to destruction rather than recirculation of internalized receptors (Gekle et al, 1995, Am. J. Physiol. 268:F899-906 and Rao et al., 1983, FEBS Lett. 160:213-216) drastically reduces HBP internalization.
- Cytochalasin D an inhibitor of actin filament polymerization (Cooper, 1987, J. Cell Biol 105:1473-1478), lowers HBP internalization by 40.6%, whereas cycloheximide, an inhibitor of protein synthesis (Ennis, 1964, FEBS Lett.399:255-258), diminishes HBP internalization.
- Colchicine an inhibitor of microtubulus assembly (Olmstead and Borisy, 1973, Ann. Rev. Biochem. 42:507-540) decreases HBP internalization by 21%.
- heparan sulfate proteoglycan-deficient Chinese hamster ovary (CHO) cells, pgsD-677 (Murphy-Ulrich et al, 1988, J. Biol. Chem. 272:24363-243670) and the corresponding wild-type CHO cells are used to study HBP internalization by FACS analysis.
- the cells are incubated with 50 ⁇ g/ml HBP for various periods of time, and HBP content is analyzed in fixed and permeabilized cells (Figure 5B). Progressive internalization of exogenously added HBP was seen over 3 hours with the wild-type CHO cells.
- Heparan sulfate-deficient cells also internalized HBP though at a considerably lower efficiency: internalization was decreased by 33% (30 min), 38% (lh) and 57% (3h), respectively in pgsD-677 cells compared to wild-type CHO-Kl (100% at each time point).
- This finding suggests that heparan sulfate-type proteoglycans are involved in HBP internalization though other sites capable of internalizing HBP must exist, e.g. chondroitin sulfate-containing proteoglycans known to be overexposed by pgsD-677 cells (Murphy-Ullrich, 1988, op. cit.).
- HBP human protein
- HBP binds with p33/gClqR. Because internalized HBP colocalizes with p33/gClqR in the vesicular fraction of HUVECs double stainings for the two proteins are performed. Endothelial cells are incubated with FITC-labeled HBP for up to 24 h, fixed and double-stained for p33 using antibodies to human p33 (from rabbit) followed by a Texas red-conjugated anti-rabbit immunoglobulin (from goat). Both FITC-conjugated HBP (green) and p33/gClqR (red) are prominent in parnuclear spots (Figure 8A).
- HUVECs are incubated for 24 hours with hHBP at the indicated concentrations.
- the medium is changed and the preincubation is followed by an 18 hours incubation in serum-free medium, to induce apoptosis.
- Control cells are incubated with Ml 99 supplemented with 10% FCS.
- DNA fragmentation is measrued by a TUNEL method.
- the results are shown in Figure 9. They indicate that there is a decrease in apoptosis in hHBP treated cells.
- HUVEC cells are treated with medium (control) and medium containing hydrogen peroxide as indicated for 18 hours in the presence or absence of hHBP for 18 hours. Apoptosis is determined as above.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Marine Sciences & Fisheries (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU13336/99A AU1333699A (en) | 1997-11-20 | 1998-11-20 | Use of heparin-binding protein for the modulation or prophylaxis of apoptosis ofmammalian cells |
EP98956825A EP1032412A1 (fr) | 1997-11-20 | 1998-11-20 | Utilisation de proteine de liaison a l'heparine pour la modulation ou la prophylaxie de l'apoptose des cellules de mammiferes |
JP2000521849A JP2002505252A (ja) | 1997-11-20 | 1998-11-20 | 哺乳類細胞のアポトーシスの調整又は予防のためへのヘパリン−結合タンパク質の使用 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK1324/97 | 1997-11-20 | ||
DK132497 | 1997-11-20 | ||
DK1394/97 | 1997-12-03 | ||
DK139497 | 1997-12-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999026647A1 true WO1999026647A1 (fr) | 1999-06-03 |
Family
ID=26065587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK1998/000510 WO1999026647A1 (fr) | 1997-11-20 | 1998-11-20 | Utilisation de proteine de liaison a l'heparine pour la modulation ou la prophylaxie de l'apoptose des cellules de mammiferes |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1032412A1 (fr) |
JP (1) | JP2002505252A (fr) |
AU (1) | AU1333699A (fr) |
WO (1) | WO1999026647A1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000026352A1 (fr) * | 1998-11-04 | 2000-05-11 | Chugai Research Institute For Molecular Medicine, Inc. | Nouvelles serine proteases de la famille de la trypsine |
WO2001016285A3 (fr) * | 1999-08-31 | 2001-09-13 | Novozymes As | Nouvelles proteases et leurs variants |
WO2003080660A3 (fr) * | 2002-03-27 | 2003-12-18 | Leukotech As | Procede de preparation d'une proteine de liaison a l'heparine (hbp) mammifere recombinee |
US7217554B2 (en) | 1999-08-31 | 2007-05-15 | Novozymes A/S | Proteases and variants thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022547906A (ja) * | 2019-09-09 | 2022-11-16 | クリスティアン-アルブレヒト-ウニヴェルズィテート ツー キール | 細胞死を阻害する化合物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996028544A1 (fr) * | 1995-03-09 | 1996-09-19 | Novo Nordisk A/S | Conjugue proteine-lipide, constitue de la proteine fixant l'heparine et d'un analogue d'un ceramide, et son utilisation pharmaceutique pour le traitement de troubles lies a des lesions causees a des cellules par diverses agressions |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5814602A (en) * | 1988-03-17 | 1998-09-29 | Novo Nordisk A/S | Heparin-binding proteins |
-
1998
- 1998-11-20 EP EP98956825A patent/EP1032412A1/fr not_active Withdrawn
- 1998-11-20 AU AU13336/99A patent/AU1333699A/en not_active Abandoned
- 1998-11-20 JP JP2000521849A patent/JP2002505252A/ja active Pending
- 1998-11-20 WO PCT/DK1998/000510 patent/WO1999026647A1/fr not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996028544A1 (fr) * | 1995-03-09 | 1996-09-19 | Novo Nordisk A/S | Conjugue proteine-lipide, constitue de la proteine fixant l'heparine et d'un analogue d'un ceramide, et son utilisation pharmaceutique pour le traitement de troubles lies a des lesions causees a des cellules par diverses agressions |
Non-Patent Citations (4)
Title |
---|
DIALOG INFORMATION SERVICES, File 155, Dialog Accession No. 09343439, MEDLINE, Medline Accession No. 98042252, BARASCH J. et al., "Ureteric Bud Cells Secrete Multiple Factors, Including bFGF, which Resuce Renal Progenitors from Apoptosis"; & AM. J. PHYSIOL., (United States), Nov. 1997, 273 (5 Pt 2), p. F757-F767. * |
DIALOG INFORMATION SERVICES, File 155, MEDLINE, Dialog Accession No. 09354396, Medline Accession No. 98060597, ZUSHI S. et al., "Role of Heparin-Binding EGF-Related Peptides in Proliferation and Apoptosis of Activated Ras-Stimulated Intestinal Epithelial Cells"; & INT. J. CANCER, (United States), 10 Dec. 1997, 73(6), p. * |
DIALOG INFORMATION SERVICES, File 155, MEDLINE, Dialog Accession No. 09354776, Medline Accession No. 98049575, TAKEMURA T. et al., "The Membrane-Bound form Heparin-Binding Epidermal Growth Factor-Like Growth Factor Promotes Survival of Cultures Renal Epithelial Cells"; & J. BIOL. CHEM., (United States), 5 Dec. 1997, * |
DIALOG INFORMATION SERVICES, File 73, EMBASE, Dialog Accession No. 05701574, EMBASE Accession No. 1994116083, SMALL D.H. et al., "A Heparin-Binding Domain in the Amyloid Protein Precursor of Alzheimer's Disease is Involved in the Regulation of Neurite Outgrowth"; & JOURNAL OF NEUROSCIENCE, (J. NEUROSCI.) (United * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000026352A1 (fr) * | 1998-11-04 | 2000-05-11 | Chugai Research Institute For Molecular Medicine, Inc. | Nouvelles serine proteases de la famille de la trypsine |
WO2001016285A3 (fr) * | 1999-08-31 | 2001-09-13 | Novozymes As | Nouvelles proteases et leurs variants |
US7217554B2 (en) | 1999-08-31 | 2007-05-15 | Novozymes A/S | Proteases and variants thereof |
US7537922B2 (en) | 1999-08-31 | 2009-05-26 | Novozymes A/S | Proteases and variants thereof |
EP2206786A1 (fr) * | 1999-08-31 | 2010-07-14 | Novozymes A/S | Nouvelles protéases et variantes associées |
US7901918B2 (en) | 1999-08-31 | 2011-03-08 | Novozymes A/S | Proteases and variants thereof |
EP2336331A1 (fr) * | 1999-08-31 | 2011-06-22 | Novozymes A/S | Nouvelles protéases et variantes associées |
US8119386B2 (en) | 1999-08-31 | 2012-02-21 | Novozymes Als | Proteases and variants thereof |
WO2003080660A3 (fr) * | 2002-03-27 | 2003-12-18 | Leukotech As | Procede de preparation d'une proteine de liaison a l'heparine (hbp) mammifere recombinee |
Also Published As
Publication number | Publication date |
---|---|
JP2002505252A (ja) | 2002-02-19 |
EP1032412A1 (fr) | 2000-09-06 |
AU1333699A (en) | 1999-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6228834B1 (en) | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof | |
CA2367750C (fr) | Tribonectines | |
AU772778B2 (en) | Novel inhibitors of angiogenesis and tumor growth | |
US6960562B2 (en) | Tribonectin polypeptides and uses thereof | |
KR100682666B1 (ko) | 항혈관형성 단백질 및 이들을 사용하는 방법 | |
US20030171547A1 (en) | Adipocyte-specific protein homologs | |
KR20030067755A (ko) | 글루코세레브로시다제 활성을 갖는 이관능성 융합 단백질 | |
IL199316A (en) | An antibody is cleared and a kit that includes it for diagnosing retinal dystrophy | |
US20030220490A1 (en) | Cell membrane directed drugs | |
US6518403B2 (en) | Antibodies that bind an adipocyte-specific protein homolog | |
CA2237051A1 (fr) | Affinite amelioree de peptides lies a l'hyaluronan | |
WO2004064857A1 (fr) | Medicaments contenant galectine 9 | |
RU2200573C2 (ru) | Связывающий гепарин белок для лечения сепсиса | |
JP4979867B2 (ja) | 新規なrg1ポリペプチドをコードするdna | |
US7084106B1 (en) | Application of a viral complement inhibitory protein in the treatment and diagnosis of Alzheimer's Disease | |
EP1032412A1 (fr) | Utilisation de proteine de liaison a l'heparine pour la modulation ou la prophylaxie de l'apoptose des cellules de mammiferes | |
CA2227972A1 (fr) | Une protease du venin du cobra, la mocarhagine, et ses utilisations therapeutiques | |
WO2000043027A1 (fr) | Utilisation d'une proteine inhibitrice du complement viral dans le traitement et le diagnostic de la maladie d'alzheimer | |
WO1999003489A2 (fr) | Procedes et compositions permettant de reguler le transport des proteines dans le noyau | |
US6803450B2 (en) | Adipocyte-specific protein homologs | |
US6759047B1 (en) | Anti-angiogenic proteins and methods of use thereof | |
US7547676B2 (en) | Antagonist peptides to the C5A chemotactic function of vitamin D binding protein | |
US20020102240A1 (en) | Methods for use for integrin b1c cell growth inhibitor | |
RU2820132C2 (ru) | Способ улучшения симптомов со стороны нижних мочевыводящих путей | |
AU2011253771B2 (en) | Method for inhibiting immune complex formation in a subject |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998956825 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1998956825 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998956825 Country of ref document: EP |